# Debate prop_0624__mimo-v2.5-pro__gpt-5.6-high__s1__tpl_placement_active_20260320f

- topic_id: prop_0624
- proposition: Health systems should permit and reimburse AI-assisted clinical documentation and triage only if models meet publicly reported accuracy and bias benchmarks.
- model_pro: mimo-v2.5-pro
- model_con: gpt-5.6-high
- side_swap: True

## Turn 1: PRO Opening

- model: mimo-v2.5-pro
- raw_words: 336
- clipped_words: 336
- claim_ids: [P1.1], [P1.2], [P1.3], [P1.4], [P1.5], [P1.6]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[P1.1] When a hospital deploys an AI system to triage patients in the emergency department or generate clinical notes that go into a medical record, it is making a consequential decision about human health. The proposition before us simply asks: before public health systems pay for these tools and integrate them into care, shouldn't we require proof that they work—and proof that works equitably?
[P1.2] Consider what reimbursement actually means. When a health system reimburses AI-assisted documentation, it is spending public or pooled funds and implicitly endorsing that technology as medically appropriate. Every other intervention that health systems pay for—drugs, devices, surgical procedures—faces some form of regulatory scrutiny and evidence threshold. AI tools that shape clinical decisions should not be exempt from this basic bargain between public investment and public accountability.
[P1.3] The triage context makes this especially urgent. An AI system that flags chest pain patients as low-risk is making life-and-death determinations. If that system has a meaningful error rate for certain populations—say, women presenting with atypical cardiac symptoms, or patients whose primary language differs from the training data—then deploying it without disclosed benchmarks means embedding those failures silently into care pathways. You cannot fix a bias you do not measure, and you cannot measure what you do not require to be reported.
[P1.4] My case rests on three pillars. First, patient safety demands that tools influencing clinical decisions meet demonstrated accuracy standards before deployment at scale. Second, equity requires that bias be actively assessed across demographic lines—not assumed away—because healthcare disparities are already severe and AI can easily widen them.
[P1.5] Third, public reporting is essential because transparency creates the feedback loop that drives improvement; proprietary claims of accuracy without independent verification are insufficient when people's lives are at stake.
[P1.6] The standard we propose is not prohibition. It is the same basic principle that governs everything else in medicine: demonstrate that your intervention works, show your evidence publicly, and prove it does not disproportionately harm vulnerable populations. Anything less treats patients as test subjects and taxpayers as venture capital.

## Turn 2: CON Opening

- model: gpt-5.6-high
- raw_words: 348
- clipped_words: 340
- claim_ids: [C1.1], [C1.2], [C1.3], [C1.4], [C1.5], [C1.6], [C1.7], [C1.8]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[C1.1] The proposition’s fatal word is “only.” It makes two blunt, static metrics a universal gate for tools with radically different risks, settings, and uses. That would block beneficial care without guaranteeing safety.
[C1.2] “Accuracy” is not one portable number. A triage model’s sensitivity, specificity, calibration, and false-negative rate matter differently depending on disease prevalence, staffing, and whether a clinician reviews its output. A documentation assistant may accurately transcribe medication names yet poorly structure billing codes; its risks are unlike autonomous triage. No public benchmark can establish that either model is safe in every hospital, language community, software integration, or workflow.
[C1.3] A model can ace a standardized test and still fail locally through alert fatigue, poor implementation, or population shift.
[C1.4] “Bias benchmarks” are even less suitable as a binary gate. Fairness has competing definitions: equal error rates, equal access, equal calibration, or improved outcomes relative to existing care. These cannot always be simultaneously satisfied when groups have different baseline risks. Requiring a model to “meet bias benchmarks” therefore hides the decisive value judgment: which measure, which groups, and what threshold?
[C1.5] Vendors will optimize for the published test while clinically important subgroups too small or locally specific to appear in it remain unprotected.
[C1.6] Public reporting also confuses transparency with effective oversight. Detailed performance should be available to regulators, purchasers, and clinicians, but mandatory public release may expose proprietary information, create incentives to teach to the benchmark, and freeze evaluation around yesterday’s model. Continuously updated systems require ongoing local surveillance, audit trails, incident reporting, and authority to suspend deployment—not a one-time public scorecard.
[C1.7] Most importantly, the rule prevents evidence generation. A health system could not permit a tightly supervised pilot, even where every output is clinician-reviewed, until benchmarks already exist. It also withholds reimbursement from safety-net providers using low-risk documentation support to reduce clerical burden, while wealthier institutions can fund experimentation privately.
[C1.8] The right protection is risk-based governance: stricter prospective validation for triage, lighter controls for clerical assistance, local testing, human oversight, and continuous monitoring. The proposition substitutes benchmark compliance for clinical judgment—and [clipped]

## Turn 3: PRO Rebuttal 1

- model: mimo-v2.5-pro
- raw_words: 340
- clipped_words: 340
- claim_ids: [P2.1], [P2.2], [P2.3], [P2.4], [P2.5], [P2.6], [P2.7], [P2.8]
- cited_claim_ids: [C1.4], [C1.7]
- missing_claim_id_refs: (none)

[P2.1] CON's case boils down to one move: attack the word "only," then offer "risk-based governance" as the alternative. But look closely at what that alternative actually requires—because it undermines itself.
[P2.2] CON concedes that accuracy matters, that bias matters, that different tools carry different risks, and that ongoing monitoring is essential [C1.2, C1.7, C1.8]. Everything CON wants is compatible with our proposition. We are not demanding a single universal threshold for all AI tools. We are demanding that whatever benchmarks exist be publicly reported and met before reimbursement flows.
[P2.3] If triage models need stricter validation than documentation tools, fine—set different benchmarks, report them publicly, and hold vendors to them. The proposition does not prohibit risk-adjusted standards; it prohibits secret standards or no standards at all.
[P2.4] CON's fairness objection actually strengthens our case. Yes, competing definitions of bias exist—equal error rates, equal calibration, demographic parity. That is precisely why public reporting matters. When a vendor privately selects the fairness metric most flattering to its product, hospitals and patients never see the tradeoffs.
[P2.5] Public benchmarking forces those value judgments into the open where clinicians, ethicists, and affected communities can debate them. CON's alternative leaves those judgments buried in vendor white papers and procurement contracts [C1.4].
[P2.6] The "teaching to the test" worry cuts both ways. Every regulatory standard faces gaming risk—drug companies optimize for trial endpoints too. We still require trials rather than trusting pharmaceutical self-assessment. The solution to imperfect benchmarks is better benchmarks, not no benchmarks.
[P2.7] CON's strongest-sounding claim is that this rule "prevents evidence generation" by blocking supervised pilots [C1.7]. But the proposition governs reimbursement and permission for clinical deployment, not research programs under independent oversight. A tightly supervised pilot generating evidence for future approval is categorically different from routine billing for an unvalidated tool. CON is conflating experimentation with deployment.
[P2.8] Finally, consider what CON's world actually looks like: local discretion, proprietary evaluations, continuous monitoring by the same institutions that purchased the tool. That is the status quo—and it has produced exactly the opacity and accountability gaps that make this proposition necessary.

## Turn 4: CON Rebuttal 1

- model: gpt-5.6-high
- raw_words: 335
- clipped_words: 335
- claim_ids: [C2.1], [C2.2], [C2.3], [C2.4], [C2.5], [C2.6], [C2.7]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[C2.1] PRO escapes the proposition by redefining it. “Whatever benchmarks exist” creates a dilemma: if benchmarks are standardized, they cannot fit radically different tasks and local populations; if each vendor or hospital chooses bespoke benchmarks, the requirement supplies no meaningful floor. A vendor can publicly report a flattering metric and still conceal the clinically decisive failure mode. Publication makes a number visible; it does not make that number valid.
[C2.2] Nor does openly debating fairness turn “bias” into a workable pass-fail gate. Suppose a triage tool improves detection for every group compared with current practice but retains unequal false-negative rates because baseline presentation and data quality differ. It could fail a parity benchmark despite reducing harm and disparities overall. The relevant question is comparative clinical benefit under local conditions, not whether a model satisfies one abstract fairness definition before anyone may use it.
[C2.3] PRO’s pilot response contradicts the text. The motion says health systems should “permit” these tools only after benchmarks are met. A supervised pilot in which clinicians use outputs on real patients is still permitted clinical use; calling it research does not create an exemption written nowhere in the proposition. And denying reimbursement during validation shifts experimentation toward wealthy institutions and away from safety-net systems whose populations most need local testing.
[C2.4] Real workflow effects—alert fatigue, language mix, integration errors—often cannot be established before such controlled use.
[C2.5] The claim that our alternative preserves opacity is also false. We explicitly support access for regulators, purchasers, and clinicians, alongside independent validation, audit trails, incident reporting, local monitoring, and suspension authority. Public summaries may supplement that system; they should not be the exclusive legal gateway.
[C2.6] The drug analogy therefore misses the clash. A high-risk autonomous triage system deserves stringent prospective evidence. A clinician-reviewed documentation assistant does not warrant the same kind of pre-permission barrier. PRO offers either an empty requirement—meet whatever benchmark someone selects—or a rigid one that delays beneficial tools and falsely reassures hospitals once a score is passed.
[C2.7] Risk-based, continuous oversight protects patients better than benchmark theater.

## Turn 5: PRO Pressure Questions

- model: mimo-v2.5-pro
- raw_words: 87
- clipped_words: 87
- claim_ids: [P3.1], [P3.2]
- cited_claim_ids: [C1.8], [C1.6], [C2.5]
- missing_claim_id_refs: (none)

[P3.1] Q1: CON proposes "risk-based governance" with stricter rules for triage and lighter rules for documentation [C1.8]. Who decides which risk category a given AI tool falls into, and what prevents vendors from self-categorizing as low-risk to avoid the very scrutiny CON agrees is necessary?
[P3.2] Q2: CON claims public reporting risks proprietary exposure [C1.6], yet supports sharing performance data with regulators, purchasers, and clinicians [C2.5]. If that information already circulates among institutional actors, what principled reason exists to exclude the patients and communities whose health is at stake?

## Turn 6: CON Pressure Questions

- model: gpt-5.6-high
- raw_words: 58
- clipped_words: 58
- claim_ids: [C3.1], [C3.2]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[C3.1] Q1: Who sets “whatever benchmarks exist,” and if thresholds vary by task, hospital, and metric, what prevents vendors from selecting flattering public measures while concealing decisive failure modes?
[C3.2] Q2: If supervised, clinician-reviewed local pilots are prohibited until public accuracy and bias benchmarks are already met, how can safety-net hospitals generate the population-specific evidence needed to establish those benchmarks?

## Turn 7: PRO Rebuttal 2

- model: mimo-v2.5-pro
- raw_words: 353
- clipped_words: 340
- claim_ids: [P4.1], [P4.2], [P4.3], [P4.4], [P4.5], [P4.6], [P4.7]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[P4.1] A1: Benchmark-setting is not uncharted territory. FDA clearance for devices, CMS coverage determinations, specialty-society guidelines—medicine already uses expert bodies to set evidence thresholds. The proposition simply extends that proven logic to AI tools. And the gaming worry is strictly worse under CON's world, where vendors choose what to share with whom, entirely in private.
[P4.2] Under public reporting, any selected metric faces open challenge from researchers, ethicists, and patient advocates. Vendors optimizing for visible benchmarks do so under a spotlight; vendors optimizing for private assessments do so in darkness. CON cannot cure the gaming problem by abolishing transparency.
[P4.3] A2: The proposition governs reimbursement and routine clinical deployment—not research protocols under independent oversight. Safety-net hospitals routinely participate in IRB-approved pilots and multi-site validation studies; that is how medical evidence has always been generated. What they cannot do is bill for unvalidated tools and call the arrangement a "pilot." CON's objection proves too much: by its logic, no intervention could ever require pre-deployment evidence, because somewhere a resource-limited institution might want to try it first.
[P4.4] That argument would dismantle drug regulation, device clearance, and surgical credentialing overnight.
[P4.5] These answers expose the central weakness in CON's case. CON wants rigorous oversight—risk-based tiers, local monitoring, audit trails, suspension authority, independent validation—everything except the one thing that makes oversight enforceable: public accountability. Every mechanism CON supports depends on institutional actors policing themselves or each other. Our proposition adds the missing layer: the public can see what works, what fails, and for whom.
[P4.6] CON's alternative is governance by procurement contract. Hospital administrators negotiate with vendors over private performance data, choose their own metrics, and report to no one outside the transaction. That is not hypothetical—it is the current landscape, and it has produced the very opacity and unchecked failures that prompted this debate.
[P4.7] The proposition draws a simple, defensible line: if you want public health dollars and clinical permission for AI that shapes patient care, prove it works, show your evidence, and prove it works equitably. Every system CON describes is compatible with that requirement. The [clipped]

## Turn 8: CON Rebuttal 2

- model: gpt-5.6-high
- raw_words: 326
- clipped_words: 326
- claim_ids: [C4.1], [C4.2], [C4.3], [C4.4], [C4.5], [C4.6]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[C4.1] A1: An independent regulator or a health system’s multidisciplinary governance body should classify tools by actual function: autonomy, clinical consequence, and degree of clinician review. Vendors submit evidence but do not make the final decision. Classification follows use, not marketing labels, and can be revised when workflows change. That prevents self-categorization without turning two metrics into a universal gate.
[C4.2] A2: There is no case for blanket secrecy. Patients should receive understandable public summaries of intended use, limitations, subgroup performance, and incidents. But granular technical files may appropriately go to accountable regulators, purchasers, and clinicians under confidentiality because of privacy, security, or legitimate proprietary concerns. The principled distinction is meaningful accountability versus compulsory publication of every benchmark as a condition of permission and payment.
[C4.3] These answers expose PRO’s false choice between “spotlight” and “darkness.” CON supports transparency; it rejects a benchmark scorecard as the mandatory gateway. Public reporting is compatible with our model, but it cannot substitute for expert access, local validation, and continuing surveillance.
[C4.4] PRO’s appeal to existing medical regulation does not solve its dilemma. Those systems use tailored benefit-risk judgments, not a universal pass on “accuracy and bias.” If thresholds are bespoke enough for each task and population, the proposition supplies no stable public floor; if standardized, they miss local language mix, prevalence, integration failures, and workflow effects. A publicly challenged metric can still be clinically wrong.
[C4.5] PRO also invents a research exception the text does not contain. A clinician-reviewed pilot on patients is still a health system permitting AI-assisted triage or documentation. Calling it “research” does not generate the local evidence beforehand, and denying reimbursement predictably disadvantages resource-poor sites.
[C4.6] The decisive comparison is patient protection over time. PRO’s gate can block a tool that improves every group yet misses one parity definition, then falsely reassure once boxes are checked. Risk-based approval, proportionate evidence, transparent summaries, monitored outcomes, and suspension authority catch real harm without sacrificing beneficial care. CON therefore wins both safety and access.

## Turn 9: PRO Closing

- model: mimo-v2.5-pro
- raw_words: 253
- clipped_words: 220
- claim_ids: [P5.1], [P5.2], [P5.3], [P5.4], [P5.5]
- cited_claim_ids: [C4.2]
- missing_claim_id_refs: (none)

[P5.1] Every oversight mechanism CON describes—risk-based classification, local validation, audit trails, suspension authority—depends on someone exercising judgment behind closed doors. Audit trails stay internal to the institution that purchased the tool. Suspension authority rests with hospital administrators who chose the vendor. Risk classification happens within governance bodies with direct financial relationships to deployment.
[P5.2] CON says they support transparency and patient access to understandable summaries [C4.2]. But throughout this debate, CON has fought to keep that transparency voluntary, selective, and gatekept by the very actors whose accountability is in question. The "principled distinction" CON draws—detailed files for regulators and purchasers, public summaries as optional supplements—is not a safeguard. It is the current arrangement.
[P5.3] It is the arrangement that has allowed AI tools to enter clinical workflows with undisclosed performance gaps and unexamined bias, because no one outside the transaction had standing to demand proof.
[P5.4] The proposition does something CON's model never does: it makes accountability structural rather than discretionary. If public money pays for a tool, and a public hospital deploys it on a public patient, the evidence must be public before reimbursement flows. That is not benchmark theater. That is the minimum condition for governance to be real rather than performative.
[P5.5] CON offers oversight without teeth. The proposition offers the one condition that prevents oversight from becoming self-congratulation: anyone can [clipped]

## Turn 10: CON Closing

- model: gpt-5.6-high
- raw_words: 213
- clipped_words: 213
- claim_ids: [C5.1], [C5.2], [C5.3], [C5.4]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[C5.1] The decisive issue is not whether transparency is valuable; it is whether two publicly reported benchmarks should be the exclusive gateway to all clinical use and reimbursement. PRO repeatedly equates visibility with validity. But a public score can still measure the wrong outcome, omit a vulnerable local subgroup, or ignore how clinician review changes risk. A visible ruler is not necessarily the right ruler.
[C5.2] PRO never resolves the core dilemma. If accuracy and bias benchmarks are tailored to each task, population, and workflow, then the proposition creates no meaningful common floor: whoever sets them can select favorable metrics. If they are standardized enough to create a firm floor, they will block tools that improve outcomes for every group merely because they miss one contested parity threshold. Either the gate is hollow or it is harmful.
[C5.3] Calling our model “oversight without teeth” does not change that. Independent risk classification, regulator access to detailed evidence, local validation, incident reporting, public summaries, and suspension authority are concrete enforcement mechanisms. They judge actual benefit and harm continuously rather than treating benchmark passage as safety.
[C5.4] Public accountability should illuminate clinical judgment, not replace it. Because the proposition makes an imperfect proxy an absolute condition—blocking beneficial, supervised care while certifying tools that may fail locally—CON provides the safer rule.
